• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, July 7, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

Bioengineer by Bioengineer
June 2, 2022
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

SAN ANTONIO (June 2, 2022) – A compound, developed by a team including scientists from The University of Texas Health Science Center at San Antonio, kills a range of hard-to-treat cancer types in petri dishes and animal models by targeting a previously unexploited vulnerability, a new study reports. The findings, published in Nature Cancer, could eventually lead to new drugs to fight these cancers, which currently have few effective treatments.

Radna Vadlamudi, PhD

Credit: UT Health San Antonio

SAN ANTONIO (June 2, 2022) – A compound, developed by a team including scientists from The University of Texas Health Science Center at San Antonio, kills a range of hard-to-treat cancer types in petri dishes and animal models by targeting a previously unexploited vulnerability, a new study reports. The findings, published in Nature Cancer, could eventually lead to new drugs to fight these cancers, which currently have few effective treatments.

“We identified a critical vulnerability in multiple cancers and have validated our findings in multiple cancer cell types and animal models,” said study leader Ratna Vadlamudi, PhD, professor of obstetrics and gynecology at UT Health San Antonio and a member of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center. “The range of cell lines and xenografts in which the compound has been shown to work is compelling and indicates that it is targeting a fundamental vulnerability in cancer cells.” Xenografts are human tumors grown in mouse models for research purposes.

The Vadlamudi lab studies breast and ovarian cancer progression, including in therapy resistance, with a goal to developing small-molecule inhibitors for therapy-resistant cancers. In 2017, he and his colleagues identified a compound called ERX-11 that targets the estrogen receptor (ER), a protein that drives the vast majority of breast cancers. From a screen of chemical analogs of ERX-11, the researchers identified that a compound called ERX-41 not only killed ER-positive cancers in petri dishes, but also readily killed triple-negative breast cancers (TNBCs), including more than 20 distinct TNBC cell lines. TNBC is a cancer subtype lacking receptors for estrogen, progesterone and human epidermal growth factor 2, and for which there is a paucity of targeted treatments.

The researchers expanded these studies to show ERX-41 had activity against a large number of human tumors grown from several of these cell lines in mouse models. In addition, ERX-41 was potent against patient-derived xenografts, as well, causing shrinkage of these human tumors grown in mouse models without affecting normal breast cells or causing any discernible toxicity in these animals. “The safety profile and high therapeutic index of this compound is particularly notable and bodes well for clinical translation,” Dr. Vadlamudi said.

Other experiments showed that in addition to ER-positive breast cancers and TNBC, ERX-41 is also effective against other cancer types with elevated endoplasmic reticulum stress, including pancreatic, glioblastoma and ovarian cancers, which all have few effective treatments. The endoplasmic reticulum is a structure in many cell types that performs assorted functions, including manufacture of proteins.

This work was performed in collaboration with scientists at UT Dallas (led by Dr. JungMo Ahn) and UT Southwestern Medical Center at Dallas (led by Dr. Ganesh Raj). ERX-41 and the related portfolio have been licensed to Dallas-based EtiraRx, which plans to move these drugs into clinical trials in early 2023.

Other researchers from UT Health San Antonio who contributed to this study include Drs. Suryavathi Viswanadhapalli, Mengxing Li, Gangadhara R Sareddy, Uday P Pratap, Zexuan Liu, Hui Yan, Zhenming Xu, Susan E Weintraub and Rajeshwar Rao Tekmal.

This research was funded by grants from the National Institutes of Health (CA223828-01 and NIH-NCI P30 CA054174).


Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress

Xihui Liu, Suryavathi Viswanadhapalli, Shourya Kumar, Tae-Kyung Lee, Andrew Moore, Shihong Ma, Liping Chen, Michael Hsieh, Mengxing Li, Gangadhara R Sareddy, Karla Parra, Eliot Blatt, Tanner C. Reese, Yuting Zhao1, Annabel Chang, Hui Yan, Zhenming Xu, Uday P Pratap, Zexuan Liu, Carlos M. Roggero, Zhenqiu Tan, Susan T. Weintraub, Yan Peng, Rajeshwar R Tekmal, Carlos L. Arteaga, Jennifer Lippincott-Schwartz, Ratna K. Vadlamudi, Jung-Mo Ahn, Ganesh V. Raj

First published: Nature Cancer, June 2, 2022

https://www.nature.com/articles/s43018-022-00389-8


The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is a primary driver for San Antonio’s $42.4 billion health care and biosciences sector, the city’s largest economic generator. Driving substantial economic impact with its five professional schools, a diverse workforce of 7,200, an annual operating budget of more than $1 billion and a clinical practice that provides more than 2 million patient visits each year, UT Health San Antonio plans to add more than 1,500 higher-wage jobs over the next five years to serve San Antonio, Bexar County and South Texas. UT Health San Antonio is the largest research university in South Texas with an annual research portfolio of approximately $350 million. To learn about the many ways “We make lives better®,” visit http://www.uthscsa.edu.

The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. Visit www.UTHealthsaMDAnderson.org.

Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.



Journal

Nature Cancer

DOI

10.1038/s43018-022-00389-8

Method of Research

Experimental study

Subject of Research

Cells

Article Title

Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress

Article Publication Date

2-Jun-2022

Share13Tweet8Share2ShareShareShare2

Related Posts

Dr. Elaine Waetjen

Less sex during menopause transition not linked to sexual pain

July 7, 2022
CIMIC mosquito control program in Sri Lanka

Climate factors predict future mosquito activity

July 6, 2022

World-first studies point way to preventing rheumatic fever

July 6, 2022

Messenger RNA technology shows promise for developing infectious disease therapeutics

July 6, 2022

POPULAR NEWS

  • blank

    Telescopic contact lenses

    40 shares
    Share 16 Tweet 10
  • Oregon State University research finds evidence to suggest Pacific whiting skin has anti-aging properties that prevent wrinkles

    38 shares
    Share 15 Tweet 10
  • The pair of Orcas deterring Great White Sharks – by ripping open their torsos for livers

    37 shares
    Share 15 Tweet 9
  • Emerging Omicron subvariants BA.2.12.1, BA.4 and BA.5 are inhibited less efficiently by antibodies

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

VaccineUrbanizationUniversity of WashingtonVirusWeaponryVehiclesZoology/Veterinary ScienceVaccinesUrogenital SystemVirologyViolence/CriminalsWeather/Storms

Recent Posts

  • Bees’ ‘waggle dance’ may revolutionize how robots talk to each other in disaster zones
  • Killing resistant prostate cancer with iron
  • Less sex during menopause transition not linked to sexual pain
  • Climate factors predict future mosquito activity
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....